Category Archives: Corporate

Healthcare stocks display their resilience after bear market struck in December; well, most do.

The News: We’re hardly in a recession, and most forms of healthcare spending remain incredibly robust, regardless of what the overall economy does and what the White House says about… Read more »

Healthcare IPO dreamers not ready to throw in the towel despite recent market slump. Will 2019 stack up to 2018?

It’s now Daylight Saving Time and the question on the heretofore gloomy minds of a lot of us healthcare stock editorialists is: Will it be boom or kaboom for IPOs… Read more »

Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”

The News: Voyager Therapeutics Inc. (Cambridge MA) struck a deal with AbbVie Inc. (North Chicago) to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s… Read more »

Healthcare IPOs keep rolling along, and not just in the US. Will March come in like a lion, or a lamb?

The News: While markets take a breather during this holiday shortened week, any big IPO news in the US will likely come in the form of new filings. A company… Read more »

Three healthcare stocks shine while two fizzle to cap the first month of 2019’s investor lottery. Who’s a rational bet and who’s a pure gamble.

The healthcare stock market’s recent success is largely dependent on the fact that, as the global population increases and more people need access to healthcare, companies in the space are prepared… Read more »

IPOs are back in business; well, unless and until there’s another government shutdown.

IPOs are back in the race for torrents of cash. The government is fully funded until February 15, which means a wave of IPOs should begin launching today (Feb. 4)…. Read more »

IPOs keep their hopes alive with new registrations

Unfazed by record government shutdown, 2019 healthcare IPOs burst out of the gate with 1 pricing and 5 filings. As expected, no IPOs priced this past week. And due to… Read more »

Spotlight on three winning stocks from the past week and one absolute washout. But buy the dud first, then see what we think about the others.

1) Axsome Therapeutics Inc. (Nasdaq:AXSM) led advancing issues, skyrocketing 180% last week to $7.36. On Jan. 7, the NYC-based company reported that its lead drug candidate, AXS-05, hit its primary endpoint in… Read more »

Health-sector investors hold breath as 2018 mercifully comes to a close; but what does 2019 portend? Anyone else cringe at prime-number years?

As investors stagger toward the New Year, adjusting their neck braces for one final lap of trading on December 31, there’s one big consolation for the recent, massive, daily twists… Read more »